Oryzon announces journal publication of final Phase IIa ALICE results with iadademstat in ... 03/06/2024 Healthcare Access to innovation Rare diseases Innovative drugs Advanced therapies The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients... Partners - Oryzon Genomics
BCN HEALTH publishes a study estimating the cost of thalassaemia care across the world 29/05/2024 Healthcare Rare diseases BCN HEALTH desarrolló un modelo de costes aplicable a nivel mundial para la atención de la talasemia. Partners - BCN Health
Oryzon selected as Associated Partner in the first Important Project of Common European In... 29/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine Financing Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia... Partners - Oryzon Genomics
Miramoon Pharma Receives Orphan Drug Designation for MP-004 28/05/2024 Healthcare Access to innovation Rare diseases Innovative drugs Orphan Drug Designation is a special status granted by the FDA to drugs that are intended to treat rare diseases or... Partners - Miramoon Pharma
Atlas Molecular Pharma successfully completes phase one in humans of its treatment for Con... 28/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine The final results of ATL-001, the biotech company's lead candidate, have shown that it is able to stabilize UROIIIS and... Partners - Inveready
BCN HEALTH will present several communications at the EASL and AASLD congresses evaluating... 27/05/2024 Healthcare Rare diseases The consulting firm specialized in the health sector will compare different quantitative data between patients suffering... Partners - BCN Health
Oryzon reports financial results and corporate update for quarter ended March 31, 2024 07/05/2024 Healthcare Access to innovation Rare diseases Personalized medicine Advanced therapies Financing Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD)... Partners - Oryzon Genomics
Mikrobiomik launches strategic investment round to advance its first medicine based on the... 30/04/2024 Healthcare Drug discovery Rare diseases Innovative drugs The Biscayan biopharmaceutical company, which plans to launch its first biological medicine into the market in the first... Partners - Mikrobiomik
BCN HEALTH publishes a study evaluating the hospital incidence and medical costs of congen... 22/04/2024 Healthcare Rare diseases BCN HEALTH has published the study ‘Hospital incidence and costs of congenital hydrocephalus in Spain: a multicenter... Partners - BCN Health
Biotechnology lays the groundwork for the present and future of healthcare and drives the ... 07/04/2024 Healthcare Drug discovery Rare diseases Personalized medicine Advanced therapies Antibiotic resistance Climate change Agrifood Animal health The health pipeline of AseBio includes 130 molecules for 150 indications being investigated by 40 national companies... AseBio
